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Letters to the editor
To the Editors:
We have read with interest the recent paper about coronavirus infections in 
children including new coronavirus disease 
(COVID-19).1 One of the central questions 
in this new coronavirus (SARSCOV2) pan-
demic is why children are less affected than 
adults.2 We think that three main hypotheses 
should be considered or studied.
 (1) Angiotensin-converting enzyme 2 
(ACE2) receptor: this receptor is 
expressed by the alveolar type 2 
cells. Maybe a lower presence of 
ACE2 in children’s lungs influences 
the clinical expression of COVID19.3 
This hypothesis should cautiously be 
considered. As it has been published, 
children with less than 1 year are the 
group at higher risk of complications. 
This population, empirically, should 
have lower ACE2 expression. In these 
cases, the presence of viral or bacte-
rial coinfections must be considered 
and promptly treated. Maybe they are 
acting as confounders.
 (2) Endothelial damage: it has been 
described that age, cardiovascular 
diseases and diabetes mellitus are 
risk factors for severe COVID19. 
In these cases, previous endothelial 
damage may facilitate and increase 
the inflammatory response to 
SARSCOV2.4,5 In healthy children, 
the endothelial damage is practically 
absent. This could help to avoid the 
spread of the inflammatory process. 
It will be of great interest to add 
knowledge about children with simi-
lar risk factors like the described in 
adults.
 (3) Innate immunity: the first line of 
defense to SARSCOV2 is the innate 
immunity. To avoid this, coronavirus 
blocks the type I interferon route to 
multiply and increase their copies. 
The innate immunity in children is 
well trained not only by community-
acquired viral infections5 but also by 
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the use of vaccines also trains it.3 The 
viral vaccines are mainly adminis-
tered from 1-year-old in advance. The 
influence of this about the response 
to SARSCOV2 infection should be 
studied. Also, the impact over the 
evolution of previously administered 
attenuated RNA vaccines should be 
analyzed. In that way, the influenza 
vaccine, which also uses the inter-
feron 1 route, may have an impact on 
the immune response. This hypothe-
sis about the influenza vaccine should 
also be considered in the adult popu-
lation.
In summary, as far as we know, 
children appear to be least affected by 
COVID19. This must be an expression of 
multifactorial causes that nowadays are not 
well defined. Added to the clinical manage-
ment, the uses of immunologic and basic 
science approaches will be of great inter-
est. With these three hypotheses, we try to 
offer a possible explanation for the differ-
ences observed with adults. The study and 
description of this hypothesis or others may 
help to develop new therapeutic or prognos-
tic tools.
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To the Editors:
We read with attention the review of Zimmerman and Curtis1 on Coronavi-
rus Disease 2019 (COVID-19) among chil-
dren and take the opportunity of this letter to 
share additional information. Infection with 
severe acute respiratory syndrome corona-
virus 2 has mostly been reported in adults, 
though a recent publication described 9 
infants <1-year-old with COVID-19.2 Among 
infant data are very few, though comparisons 
with infections due to other coronavirus 
strains will be helpful. The Pneumo-Study3 
on the etiologic agents of pneumonia in chil-
dren <5-year-old conducted by the Merieux 
Foundation Global Approach to Biological 
Research, Infectious diseases and Epidemics 
in Low-income countries (GABRIEL) net-
work provides opportunities for comparisons.
We compared the published clinical 
features of hospitalized infants with COVID-
192 and hospitalized infants infected with 
other coronavirus strains or influenza from the 
GABRIEL project. The incident case-control 
Pneumo-study was done in children less than 
5 in low-/middle-income countries between 
2010 and 2014. The protocol and initial results 
are detailed elsewhere.3,4 The population was 
restricted to infants <1-year-old with features 
of pneumonia (ie, cases).3 Nasopharyngeal 
swabs were collected at admission to identify 
bacteria and viruses by reverse-transcription 
polymerase chain reaction (RT-PCR). Statis-
tics were restricted to the same variables used 
by Wei et al2 and to cases with positive swabs 
for a coronavirus or influenza virus.
Of the 333 infants with pneumonia, 
17 had CoV-positive nasopharyngeal swabs 
[7 (41.2%) with HKU1, 5 (29.4%) with 
CoV OC43, 3 (17.7%) with CoV NL63, 
2 (11.8%) with CoV 229E] and 31 had an 
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influenza-positive swab [22 (71%) with Influ-
enza A, 9 (29%) with Influenza B]. Cough 
seems less prevalent in COVID-19 compared 
with other infected infants (Table 1). While 
no deaths occurred in infants with COVID-
19,2 3 infants infected with CoV in Pneumo-
study died, 2 of whom were co-infected with 
Streptococcus pneumoniae.
This report underscores the lack of 
major differences in the clinical features of 
severe acute respiratory syndrome coronavirus 
2 and other types of CoV or influenza infections 
among infants despite limited clinical features 
reported. COVID-19 infection does not seem 
more severe than other CoV or influenza infec-
tions in this population, possibly as all infect 
Angiotensin-Converting Enzyme 2 receptors 
in the upper airways. As influenza,5 the con-
tribution of infants to the spread COVID-19 
should be investigated. S. pneumoniae was co-
detected in the CoV-infected infants who died 
in Pneumo-study while bacterial co-detection 
was not reported by Wei et al.2 Infants in both 
studies2,3 were hospitalized limiting selection 
bias but small sample sizes weakened statis-
tical power. The incidence of COVID-19 in 
infants less than 1-year-old is currently low, but 
studies are needed to describe the clinical fea-
tures, prognosis and impact of infected infants 
on the COVID-19 spread.
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TABLE 1. Comparison of the Characteristics of Coronavirus Disease 2019, 
Other Coronavirus and Influenza Infections Among Infants < 1-yr-old
Characteristics
Patients* With  
CoV Pneumonia 
From GABRIEL 
Pneumo-study  
(n = 17)†
(A)
Patients*  
With Influenza  
Pneumonia From 
GABRIEL  
Pneumo-study  
(n = 31)‡
(B)
Patients*  
Infected  
with COVID-19 
from Wei  
et al2 (n = 9)
(C)
Comparison 
(A) vs. (C)
P§
Comparison 
(B) vs. (C)
P§
Male gender, n (%) 9 (52.9) 17 (54.8) 2 (22.2) 0.22 0.13
Median age, mo  
(min–max)
9 (3–11) 8 (2–11) 7 (1.9–11) 0.25 0.45
Median time between 
admission and  
diagnosis, d (min–max)
0 (0–2) 0 (0–2) 1 (1–3) 0.04 <0.001
Fever > 38°C, n (%) 12 (70.6) 20 (64.5) 4 (44.4) 0.65 0.99
Cough, n (%) 17 (100.0) 31 (100.0) 2 (22.2) <0.001 <0.001
Rhinopharyngitis or 
runny nose, n (%)
7 (46.7)¶ 6 (23.1)║ 1 (11.1) 0.19 0.99
Death, n (%) 3** (17.7) 1 (3.3) 0 (0.0) 0.53 0.99
*Detected by RT-PCR in nasopharyngeal swab.
†CoV OC43, n = 5 (29.4%). CoV NL63, n = 3 (17.7%). CoV 229E, n = 2 (11.8%). CoV HKU1, n = 7 (41.2%).
‡Influenza A virus, n = 22 (71.0%). Influenza B virus, n = 9 (29.0%).
§Qualitative variables were compared with Fisher exact tests; quantitative variables, Wilcoxon tests.
¶n = 15.
║n = 26.
**One with NL63, 1 with HKU1, 1 with OC43.
CoV indicates coronavirus; COVID-19, Coronavirus Disease 2019; GABRIEL, Global Approach to Biologic Research, 
Infectious diseases and Epidemics in Low-income countries; RT-PCR, reverse-transcription polymerase chain reaction.
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To the Editors,
We read with interest the recent article published by Chidini et al1 referring 
to the challenges encountered in the man-
agement of severe acute respiratory syn-
drome coronavirus 2 infection in children in 
Milan. This is actually the current situation 
in various pediatric departments throughout 
Europe. We fully agree with the suggested 
management and approach, although the lat-
ter still poses major further logistical issues 
such as the availability of negative pres-
sure rooms for all inpatients with suspected 
COVID-19 infection pending virologic con-
firmation. Moreover, 2 negative respiratory 
samples are required to rule out severe acute 
respiratory syndrome coronavirus 2 infec-
tion which means further inpatient stay and 
more resources needed. More data in the 
field are urgently required to guide the pedia-
tricians further.
